Enzychem Lifesciences
Jeremy Ricci currently serves as the CMC General Manager at Enzychem Lifesciences, where responsibilities include developing CMC and regulatory strategies, preparing various regulatory documents, managing collaborations for manufacturing and analytical developments, and maintaining relationships with regulatory agencies. Previously, Jeremy held the position of CMC/Regulatory Affairs Manager and Medicinal Chemistry R&D Manager at Yonsung Fine Chemicals, and served as Deputy General Manager at Nanoresource, focusing on research and development of nanodiamond applications. At Wooshin Medics Ltd., Jeremy worked as a Senior Researcher on drug product development, and previously held research positions at Yonsei University, specializing in the synthesis and biological evaluations of anticancer agents. Jeremy earned a Ph.D. in Organic Chemistry from Université Côte d'Azur.
This person is not in any teams
This person is not in any offices
Enzychem Lifesciences
Enzychem Lifesciences, Corp. (KOSDAQ:183490) is a global biopharmaceutical company headquartered in Seoul, Korea, which is dedicated to developing new drugs and APIs (Active Pharmaceutical Ingredients). Since its foundation in 1999, Enzychem Lifesciences has been striving to develop new and innovative treatments capable of addressing unmet medical needs with R&D-driven approaches under its grand mission of "Saving Human Lives by Overcoming Unmet Medical Needs" EC-18, the lead compound of Enzychem Lifesciences, is an immune modulator driven from deer antler that has the potential to be used for a variety of indications. At present, three clinical trials for different indications are being conducted; Chemotherapy Induced Neutropenia (CIN), Chemoradiation Induced Oral Mucositis (CRIOM), and Acute Radiation Syndrome (ARS). In order to facilitate the clinical trial process, Enzychem launched a US operation office in New Jersey on June 28, 2018. Currently, Enzychem Lifesciences is one of the fastest growing life science companies in KOSDAQ Stock Exchange in terms of market capitalization. The company is headquartered in Seoul, Korea.